Growth Metrics

Gilead Sciences (GILD) Net Income Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 76.51%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 131.31%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 109.43%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -51.68%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -13.81%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 27.11%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -146.62%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 5.72%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 27.11%
Dec 31, 2025 15.68%
Sep 30, 2025 19.55%
Jun 30, 2025 19.99%
Mar 31, 2025 378.54%
Dec 31, 2024 67.97%
Sep 30, 2024 -21.46%
Jun 30, 2024 2.11%
Mar 31, 2024 -64.14%
Dec 31, 2023 -2.84%
Sep 30, 2023 83.24%
Jun 30, 2023 32.20%
Mar 31, 2023 -13.83%
Dec 31, 2022 32.56%
Sep 30, 2022 52.25%
Jun 30, 2022 -15.41%
Mar 31, 2022 -81.73%
Dec 31, 2021 -4.23%
Sep 30, 2021 7.20%
Jun 30, 2021 -5.87%
Mar 31, 2021 3.82%
Dec 31, 2020 34.26%
Sep 30, 2020 -49.32%
Jun 30, 2020 -45.66%
Mar 31, 2020 -17.09%
Dec 31, 2019 -39.07%
Sep 30, 2019 -32.97%
Jun 30, 2019 -18.76%
Mar 31, 2019 -17.98%
Dec 31, 2018 -54.96%
Sep 30, 2018 -22.97%
Jun 30, 2018 -26.04%
Mar 31, 2018 -29.18%
Dec 31, 2017 -45.20%
Sep 30, 2017 -0.15%
Jun 30, 2017 -5.62%
Mar 31, 2017 6.68%
Dec 31, 2016 57.95%
Sep 30, 2016 61.78%
Jun 30, 2016 65.77%
Mar 31, 2016 70.65%
Dec 31, 2015 83.41%
Sep 30, 2015 89.85%
Jun 30, 2015 85.36%
Mar 31, 2015 114.73%
Dec 31, 2014 73.60%
Sep 30, 2014 54.58%
Jun 30, 2014 70.04%
Mar 31, 2014 50.87%
Dec 31, 2013 7.88%
Sep 30, 2013 3.80%
Jun 30, 2013 2.68%
Mar 31, 2013 -5.56%
Dec 31, 2012 -20.53%
Sep 30, 2012 0.03%
Jun 30, 2012 7.45%
Mar 31, 2012 -9.31%